Our cells produce spike protein variants that have lost the important membrane anchor, resulting in secreted soluble spike protein variants which end up in our blood circulation. Soluble spike protein has been described to cause adverse effects, e.g., a strong inflammatory response on endothelial cells. Moreover, nearly all severe cases of SARS-CoV-2 infections (COVID-19) suffer from life-threatening thromboembolic events due to the many spike surface protein in the bloodstream. Even pseudoviruses with spike protein on the surface cause strong inflammatory reactions in tissues and endothelial cells, indicating the danger of this protein. When this spike protein ends up in our circulation, such thromboses may occur in any site of the human body where endothelial cells express ACE-2. When the immune system starts to produce antibodies against the spike protein, the endothelial cells will not only bind the soluble spike protein variants but would also be attacked with the newly formed antibodies. This will give rise to strong inflammatory reactions. (Kowarz, Krutzke, & Reis, 2021)